HIV

Pharmalot By Ed Silverman

Once-a-day pills for combating HIV are a better deal than some people think

Pharmalot By Ed Silverman

Gilead’s HIV prevention pill can greatly reduce new infections in targeted rollouts

Business By Lev Facher and Ike Swetlitz

Aetna faces class-action lawsuit over HIV disclosures

Health By Erin Mershon

Insurer’s mailing to customers made HIV status visible through envelope window

Health By Bob Tedeschi

Homeless and sick, he ended up in a place where loved ones could find him

Health By Helen Branswell

Patient Zero in AIDS crisis was misidentified, study says, rewriting early history of virus

In the Lab By Sharon Begley

CRISPR identifies genes that might be targeted to hobble HIV infection

Pharmalot By Ed Silverman

Gilead asks FDA to expand exclusivity for a key HIV drug

In the Lab By Shayla Love

Genetic fossil-hunters dig through HIV’s long history for clues to new treatments

In the Lab By Andrew Joseph

A drug used to treat Crohn’s disease could suppress HIV, monkey study suggests

Health By Dylan Scott

In Trump’s America, towns in poor health don’t think he will save them

Heavyweights By Rebecca Robbins

The drug pricing crusader at the center of one of the nastiest fights of the election season

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: FDA approves a biosimilar version of Enbrel

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Glaxo believes its plan for HIV treatment is a ‘game changer’

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Another analysis finds new cholesterol drugs are not cost-effective

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Gilead’s preventive HIV pill must be covered in England

Health By Lindzi Wessel

High rates of injection drug use increases gay teens’ HIV risk

First Opinion By Peter Piot and Mitchell Warren

Prevention must be at the forefront to meet global HIV goals

Health By Ike Swetlitz

HIV drugs protect against transmission, even in unprotected sex

Pharmalot By Ed Silverman

Gilead’s new price hikes on HIV drugs anger AIDS activists

Business By Rebecca Robbins

Gilead hikes price of HIV therapies, other drugs by up to 10 percent

In the Lab By Eric Boodman

Inside a monkey lab, research gets fast-tracked in the ‘Zika room’

First Opinion By Benjamin Mazer

We are not viruses: Don’t limit gay men from donating blood

First Opinion By Anthony S. Fauci and Deborah L. Birx

An AIDS-free world is possible, but do we have the will to achieve it?

Health By Helen Branswell

HIV rates soar among Southern men who have sex with men